| Name | Title | Contact Details |
|---|
XL Health is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At VSP Global, we activate the full power of care by consciously reinvesting in greater vision, health, and opportunities for all. Our mission is to help people see every possibility—and we do that through our strategic business pillars that work together to connect nearly 90 million patients to network doctors in a variety of settings across the globe. When you become a VSPeep, you join a group of thinkers, doers, adventurers, risk-takers, and boundary pushers who think outside the peripheral to develop products, programs, and services that help create a world where everyone can bring their best vision to life. The VSP Global Values are: We care, We trust, We empower diversity, and We are one team. Join the power of our purpose and check out job opportunities with VSP Global and its strategic businesses, including: VSP Vision Care, Marchon Eyewear, Altair Eyewear, VSP Optics, Eyefinity EHR, VSP Retail, VSP Ventures, and Eyes of Hope (our charitable giving platform).
Ramona Vna and Hospice is a Hemet, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Newly combined with Baxalta, Shire is now the leading global biotechnology company focused on serving people affected by rare diseases and highly specialized conditions. These diseases are often misunderstood, under-diagnosed, and potentially life-threatening. Our 22,000 employees come to work every day with a common purpose: to develop and deliver breakthrough therapies that enable people with life-altering conditions to live their lives to the fullest. At Shire, we are dedicated to expanding, building and sustaining leadership across our key therapeutic areas through our extensive portfolio of products, innovative pipeline and collaborative approach to working with diverse partners around the globe. We strive to earn and keep the trust of our patients, their families and physicians, and all others who support and advance their care. Working together, the possibilities for our patients, healthcare partners and employees are unprecedented, with significant growth potential for our shareholders.